Cambrex Completes $38 Million API Plant Expansion
Manufacturing capacity of company’s High Point facility now doubles as a result.
Cambrex, a contract development and manufacturing organization (CDMO) that offers drug substance, drug product, and analytical services across the entire drug lifecycle,has completed of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, NC. This expansion doubles the facility's manufacturing capacity, with new state-of-the-art analytical and chemical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation with three work centers and 2,000-liter reactors.
The High Point capabilities complement those of previously acquired Snapdragon Chemistry, which specializes in R&D for API batch, and continuous flow process development. The combination of Snapdragon Chemistry and the expansion in High Point allows clients to utilize one vendor for flow chemistry scale-up from R&D through commercialization.
"When we began this project in 2021, our vision extended far beyond capacity," comments Tom Loewald, CEO, Cambrex. "We designed a facility that can continue to deliver on client needs as the industry evolves, with state-of-the-art technology and laboratory equipment, an energy-efficient infrastructure, and clinical to commercial manufacturing scale."
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
